Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | DRD5 | P21918 | 5/20 | 0.47 |
| ▸ | DRD1 | P21728 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083358 | 0.89 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL10871080 | 0.87 | NPSR1 (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12969652 | 0.85 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL13452416 | 0.82 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12363802 | 0.79 | MAOA (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29507212 | 0.79 | MAOA (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL17721296 | 0.79 | MAOA (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL26027881 | 0.78 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24265736 | 0.78 | MAOA (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL470075 | 0.78 | DRD2 (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | disclosed |
| EP-3543242-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | Impact Therapeutics, Inc (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | ADRA2A 3040/4885ADRA2B 3675/4885ADRA2C 2739/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | ADRA2A 3040/4885ADRA2B 3675/4885ADRA2C 2739/4885 |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | ADRA2A 3040/4885ADRA2B 3675/4885ADRA2C 2739/4885 |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | ADRA2A 74/4885ADRA2B 71/4885ADRA2C 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.